Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Evofem Biosciences Announces Padagis Will Not Seek FDA Approval To Market A Generic Version Of Phexxi Until Evofem's Phexxi Patents Expire

Author: Benzinga Newsdesk | September 27, 2023 08:49am

-- Padagis Determined They Will Not Challenge the Phexxi Patents --

-- Evofem Has Phexxi Patent Protection Through 2033 --

Posted In: EVFM